active immunotherapy


Also found in: Encyclopedia.

Active Immunotherapy

The administration of substances to evoke a protective immune response by evoking the formation of specific antibodies.

active immunotherapy

The administration of substances to evoke a protective immune response in the form of specific antibodies. Cf Passive immunotherapy, Vaccine.
Mentioned in ?
References in periodicals archive ?
INO-5150, an active immunotherapy targeting both PSA and PSMA antigens which are present in the majority of prostate cancer cells, is administered with and without INO-9012, Inovios DNA-based IL-12 immune activator.
Listed on Alternext Paris since 2010, Neovacs is a biotechnology company focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune and/or inflammatory diseases.
In terms of active immunotherapy and the type of technology we're developing, they've undergone an evolution in the last three or four years.
B-cell malignancies are good candidates for active immunotherapy.
The CAS found no differences in asthma symptoms between the active immunotherapy and placebo groups.
In the best of situations, I would expect only 25%-30% of people in this older age group with Alzheimer's would be likely to mount sufficient antibody response to remove plaques with active immunotherapy," he said.
This novel peptide is significant because it could provide the basis for an active immunotherapy that uses T-cells to attack and destroy cancer cells that overexpress the HER-2 antigen," stated Gail Maderis, president of Genzyme Molecular Oncology.
Coley's work is a primitive example of what today is known as active immunotherapy, wherein patients are given something designed to activate their immune system against cancer.
Immunocellular Therapeutics, who will present the latest clinical results in utilizing active immunotherapy against cancer stem cells in solid tumors
UNS' ongoing Phase 2 active immunotherapy trial of UB-311 in early-to-mild AD patients is fully enrolled.
INO-3112, an active immunotherapy targeting HPV 16/18 combined with a DNA plasmid for IL-12 as an immune activator, is designed to activate patients immune responses to specifically target and kill HPV associated tumors.
Researchers hypothesize that reducing alpha-synuclein accumulation will be neuroprotective; Affiris is using active immunotherapy to test that theory and develop a disease-modifying treatment.